Hemispherx BioPharma, Inc Share Price Nyse
Equities
US42366C1036
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | - | Sales 2025 * | 2.57M 214M | Capitalization | 21.37M 1.78B |
---|---|---|---|---|---|
Net income 2024 * | -27M -2.25B | Net income 2025 * | -28M -2.34B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 8.31 x |
P/E ratio 2024 * |
-0.79
x | P/E ratio 2025 * |
-0.91
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.01% |
Latest transcript on Hemispherx BioPharma, Inc
Managers | Title | Age | Since |
---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 71 | 17/08/17 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 04/22/04 |
Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 28/23/28 |
William Mitchell
CHM | Chairman | 89 | 01/98/01 |
Thomas Equels
CEO | Chief Executive Officer | 71 | 17/08/17 |
1st Jan change | Capi. | |
---|---|---|
-2.73% | 103B | |
+1.56% | 95.28B | |
+1.46% | 22.15B | |
-16.57% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-12.95% | 16.05B | |
+5.26% | 13.68B | |
+33.88% | 12.17B |